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I. Introduction
Racial and ethnic minorities persistently classify as low performance with respect to
health indicators.1 Specifically, infants born to black women are 1.5 to 3 times more likely to
die before their first birthday than those born to women of other races/ethnicities and cancer is
the second leading cause of death for most racial and ethnic minorities.2 Even more, African
Americans, American Indians, and Alaska Natives are twice as likely to have diabetes as white
individuals.”3 Health disparities, as defined by the National Conference of State Legislatures
[hereinafter the NCSL], “refers to population specific differences in the presence of disease,
health outcomes, quality of health care and access to health care services that exist across racial
and ethnic groups.” 4 Because of these low health indicators it would seem that minorities,
particularly African Americans, would take measures to improve their health. However, the
opposite holds true. African Americans are regarded as distrustful of clinical research which in
turn impacts health outcomes and quality of life. This paper will address African American
perceptions of clinical research and how those perceptions in turn negatively impact the health
decisions of this minority group. A public health and community based health approach that
educates minorities on the legal and ethical protections available should be explored to alter
minority perceptions.
Supporters of efforts to improve African American health defend the notion that the
pharmaceutical industry can assist in debunking African American perceptions of clinical
1.
National Conference of State Legislature [hereinafter NCSL], Disparities in Health, available at
http://www.ncsl.org/issues-research/health/health-disparities-overview.aspx, (Jan. 2012).
2.
Id. See also Joon-Ho Yu, Sara Goering, Stephanie M. Fullerton, Race-Based Medicine and Justice as
Recognition: Exploring the Phenomenon of BiDil, 18 Cambridge Quarterly of Healthcare Ethics (UK), 57, (2009)
also stating that racial health disparities have been documented for cardiovascular disease, cancer, diabetes,
HIV/AIDS, and numerous other diseases; Department of Health & Human Services, Fact Sheet: Preventing Infant
Mortality, press release at http://www.hhs.gov/news/factsheet/infant.html (2006) last accessed Apr. 20, 2013
defining infant mortality as an infant dying before his/her first birthday.
3.
Id.
4.
Id.
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research.5 Yu and his co-authors “believe that African American community leaders capitalized
on an opportunity to bring attention to African American health issues” with respect to the drug
BiDil a heart failure drug. 6 BiDil is linked to remedying health care disparities because it
specifically targets the African American population who disproportionately suffer from heart
disease.7 The link between improving health care disparities and pharmaceutical drug marketing
research is one mechanism to further decrease the disparities between minorities and other racial
populations. Marketing is a powerful tool to not only advance the pharmaceutical drug’s profit
margin but to also educate the minority population on the advantages of seeking treatment.
Part I of this paper will introduce the issues surrounding public perceptions of clinical
research and the access issues in the African American community.

Part II will explore

historical clinical practices and outline early historical events, the current paradigm implemented
in current drug development and clinical trials, and minority perspectives on recent
developments. Part III will explore health indicators specifically access to pharmaceutical drugs
as a health indicator. Part IV will then discuss the drug BiDil and how it has improved minority
perceptions in clinical research; it will also set forth several of the criticisms of the development
and approval history of the drug. Part V will address methods of improving addressing minority
perceptions of clinical research through public health and community based education programs
that specifically target African American populations.
recommendations.

5.
6.
7.

Yu et. al, supra note 2.
Id.
Id.
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Part VI will conclude with

II. Historical “Clinical” Practices
Historically, African Americans were discriminated against not only in social and cultural
contexts, but were also discriminated against in health care clinical research practices. 8
Unfortunately, “the deeply ingrained habits, customs, and practices of racism are not easily
uprooted.”9 Before civil rights legislation was passed, hospitals prevented African American
patients and physicians from using their facilities. 10 Despite legislative efforts to equalize
treatment between whites and minorities, separate but equal legislation only perpetuated
discrimination and inferior treatment of minorities by providing federal funds to health care
entities who maintained racially segregated facilities. 11 “Until 1964, the nation infused either
slavery, legal subordination, or overt cultural subordination into its health care system.”12 Title
VI of the Civil Rights Act of 1964 made it illegal for health care entities receiving federal
funding to discriminate on the basis of race.13
African American attitudes of health care research are linked to racism towards
minorities by the medical community.14 Looming doubts about “the true intentions” of health
care providers furthers the divide in the provision and advancement of health care between

8.
Patricia A. King, The Law-Medicine Center 50th Anniversary Symposium: The Field of Health Law: Its
Past and Future: Reflections on Race and Bioethics in the United States, 14 HEALTH MATRIX 149 (2004). Stating
that differential and negative treatment of African Americans was pervasive in the health care system in the early
20th century with studies such as Tuskegee.
9.
Id. at 151.
10.
Brian D. Smedley, et. al., Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care,
Institute of Medicine. Washington D.C.: National Academic Press (2002).
11.
See Simkins v. Moses Cone Memorial Hosp., 323 F.2d 959 (5th Cir. 1963), cert. denied, 376 U.S. 938
(1964).
12.
King supra note 1 at 151.
13.
Civil Rights Act of 1964, Pub. L. No. 88-352, 78 Stat. 240 (codified as amended at 42 U.S.C. §§ 2000d2000d-1 (2000)).
14.
Harriet A. Washington, MEDICAL APARTHEID: THE DARK HISTORY OF MEDICAL
EXPERIMENTATION ON BLACK AMERICANS FROM COLONIAL TIMES TO THE PRESENT (Doubleday)
(2007).
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African Americans and Caucasians. 15 The Tuskegee Syphilis Study is the most notorious
historical event that is often attributed to minority distrust of clinical research; 16 however,
distrust of clinical research among blacks began prior to public awareness of what actually
occurred.17 In the antebellum south, African Americans were often used on “dissecting tables,
operating amphitheaters, classroom or bedside demonstrations, and experimental facilities.” 18
Blacks were a particularly vulnerable population as they were easily identified because of their
skin color and lack of protection in the eyes of the law.19
During this time antebellum period many medical institutions requested black patients for
their facilities.20 This was particularly attractive for slave owners who could send their slaves for
low-cost treatments and beneficial for these medical institutions that needed test subjects.21 Even
though whites were also used as subjects during this time, blacks were used in far greater
proportion.22
Two notable events occurred prior to the turn of the 20th century. The first involved
John “Fed” Brown, a slave who was subjected to experiments at the hands of a Georgia
physician, Dr. Hamilton. 23 Dr. Hamilton was performing experiments to determine how to

15.
Isabel Wilkerson, Medical Experiments Still Haunt Blacks, N.Y. TIMES, June 3, 1991, available at
query.nytimes.com/gst/fullpage.html?res=9D0CEEDD1E38F930A35755C0A967958260 [hereinafter Wilkerson];
Vanessa Northington Gamble, Under the Shadow of Tuskegee: African-Americans and Health Care, 87 AM. J.
PUB. HEALTH 1773, 1776 (1997) [hereinafter Under the Shadow]. See also Ronald Roach, History's Burden:
After Decades of Neglect, an Academic Research Agenda is Being Built Around Health Disparities, 20 BLACK
ISSUES
HIGHER
EDUC.
1,
18
(May
8,
2003),
available
at
findarticles.
com/p/articles/mi_m0DXK/is_6_20/ai_101939864 [hereinafter History's Burden].
16.
Discussed in II.A, infra page 6.
17.
Under the Shadow at 1773.
18.
Todd L. Savitt, “The Use of Blacks for Medical Experimentation and Demonstration in the Old
South,”JOURNAL OF SOUTHERN HISTORY 331 (1982).
19.
Id. at 332.
20.
Id. at 333.
21.
Id.
22.
Under the Shadow at 1774.
23.
Louis Alexis Chamerovzow, Slave Life in Georgia: A Narrative of the Life, Sufferings, and Escape of John
Brown,
A
Fugitive
Slave
Now
in
England,
electronic
edition,
45
available
at
http://docsouth.unc.edu/neh/jbrown/jbrown.html.
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remedy sun-stroke.24 In Brown’s recount of the events he described how Dr. Hamilton asked
permission of his owner, Stevens, who “never inquired what was going to be done” and even if
Brown had known what was going to be done he could not himself refuse participation.25 Dr.
Hamilton had a hole dug into the ground filled with wood and set a fire.26 Dr. Hamilton then
forced Brown into the pit naked to sit with various mechanisms maintaining the heat inside.27
Brown was provided with various medications; however, the experiments did not conclude until
after Brown passed out.28 Between the series of experiments Brown was placed on a diet and
bled every other day; after he became weak from this experiment Dr. Hamilton began an
experiment to ascertain how deep Brown’s skin went. 29 In an effort to ascertain how deep
Brown’s skin went Dr. Hamilton he applied blisters to Brown’s hands, legs, and feet and
continued to create blisters until a layer of dark skin formed.30
In a second event, a study conducted in Alabama slaves were used for gynecological
experiments. Dr. J Marion Sims, now known as the founder of modern surgical gynaecology,
developed an operation for the cure of vesicovaginal fistula.31 Dr. Sims was able to develop this
cure by using slave subjects that he housed in hospital behind his home in Montgomery,
Alabama.32 One slave in particular underwent thirty operations by Dr. Sims, who was able to
repair holes in her bladder and rectum.33 In total, Dr. Sims had seven subjects who involuntarily

24.
Id.
25.
Id.
26.
Id. at 46.
27.
Id.
28.
Id.
29.
Chamerovzow, supra note 23 at 47-48.
30.
Id. at 48; see also Alondra Nelson, Unequal Treatment, Washington Post, Jan. 7, 2007 at
http://www.washingtonpost.com/wp-dyn/content/article/2007/01/05/AR2007010500180.html last accessed Apr. 20,
2013 stating that the study to determine how deep Brown’s skin went was without therapeutic value.
31.
LL Wall, The Medical Ethics of Dr. J Marion Sims: A Fresh Look at the Historical Record, 32 (6) J. MED.
ETHICS 346 (2006).
32.
Id.
33.
Id.
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underwent experimentation.34 Procedures were performed without anesthetics, and one subject
almost died. 35 Experiments such as this and the one involving John Brown were only the
beginning of unethical experiments that finally culminated with the Tuskegee experiment.
A. The Tuskegee Syphilis Study
A seminole event in the realm of race, genetics, and research is the Tuskegee Syphilis
Study. The Tuskegee study began in 1932 at the behest of the United States Public Health
Services [hereinafter USPHS] in collaboration with the Tuskegee Institute. 36 The study was
entitled “Tuskegee Study of Untreated Syphilis in the Negro Male,” which aimed to study the
effects of syphilis on black males.37 These results would then be used to validate certain drug
treatments targeted for minorities.38
There were 600 subjects involved in the study; of that number 399 had syphilis while 201
were disease free.39 Black men, most of which were sharecroppers, between 25 and 60 years old
were targeted for the study, especially those who tested positive for the disease.40 The black men
were told they were being treated for “bad blood” and subjected to research without their

34.
Durrenda Ojanuga, The Medical Ethics of the Father of Gynaecology, Dr J Marion Sims, 19 J. MED.
ETHICS 28, 29 (1993).
35.
Id.
36.
American Health Lawyers Association, Patient-Tailored Medicine, Part One: The Impact of Race and
Genetics on Medicine, Vol. 2 No. 1 J. HEALTH & LIFE SCI. L. 1, 11 (2008); see also CDC, U.S. Public Health
Services
Syphilis
Study
at
Tuskegee:
The
Tuskegee
Timeline,
available
at
http://www.cdc.gov/tuskegee/timeline.htm (2011) [hereinafter The Impact of Race & Genetics].
37 .
Tuskegee Timeline.
38.
Id.
39.
Id. see also Tuskegee Syphillis Study Ad Hoc Advisory Panel, Final Report: Report on Charge 1-A (Apr.
28, 1973), biotech. law.lsu.edu/cphl/history/reports/tuskegee/report1.pdf [hereinafter Report on Charge I-A] stating
that the researchers never actually documented the reason for the study and that the subjects to the study were not
given information about possible effects of the study.
40.
Allan M. Brandt, Racism and Research: The Case of the Tuskegee Syphilis Experiments, in TUSKEGEE'S
TRUTHS: RETHINKING THE TUSKEGEE SYPHILIS STUDY 1, 15, 18 (Susan M. Reverby ed., University of
North Carolina Press) (2000), available at http://www.sociology101.net/readings/Racism-And-Research.pdf
[hereinafter Racism and Research].
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informed consent. 41 Unfortunately, the treatments involved did not cure the disease and the
treatments that were supposed to only last six months went on for forty years. 42 The men
received medical exams, free food, and burial insurance as compensation for their participation
in the study.43
The study was conducted in Macon County, Alabama.44 Macon County was particularly
interesting for the researchers because evidence obtained during demonstration studies during
1930-1932 showed a high rate of syphilis among the black population in Macon.45 These initial
demonstration studies were funded by the Julius Rosenwald Fund.46 Culturally, this population
was poorly viewed and vulnerable because the illiteracy rate was pervasive.47 Later research was
financially supported by the USPHS and a grant from the Milbank Memorial Fund which gave
$50 to each of the subjects for their participation in the study.48
The fact still remains, “treatment [that] could have cured them was deliberately withheld,
and many of the men were prevented from seeing physicians who could have cured them.”49
Penicillin became available in the early 1950s which could effectively treat the disease.50 In
1969, the Tuskegee study was reaffirmed by the Center for Disease Control and even gained

41.
Tuskegee Timeline.
42.
Id.
43.
Id.
44.
Tuskegee
University,
About
the
USPHS
Syphilis
Study,
available
at
http://www.tuskegee.edu/about_us/centers_of_excellence/bioethics_center/about_the_usphs_syphilis_study.aspx
(2013).
45.
Report on Charge I-A at 2.
46.
Racism and Research at 2-3.
47.
Id.
48.
Id.
49.
Racism and Research at 1.
50.
Id. See also Tuskegee Timeline which states that in 1945 Penicillin was accepted as the preferred treatment
for syphilis, 1947 USPHS established “Rapid Treatment Centers” to treat syphilis, but the men involved in the study
were prohibited from obtaining treatment.
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support of medical associations such as the American Medical Association and National Medical
Association.51
The study did not end until 1972 when the Department of Health, Education, and Welfare
[hereinafter HEW] insisted that the study cease after news media reported on the existence of the
study.52 Only seventy-four of the subjects were alive when the study was brought to public
attention.53 HEW appointed an investigatory committee which found, among other things, that
the study was unethical and the benefits of the study were not justified in comparison to the
enormous risk undertaken by the subjects. 54 The study “has come to symbolize racism in
medicine, misconduct in human research, the arrogance of physicians, and government abuse of
black people.”55
In 1997, President Clinton apologized on behalf of the nation and recognized that this
atrocity had far reaching effects that extended beyond the participants in the study.56 President
Clinton remarked, “an apology is the first step, and we take it with a commitment to rebuild that
broken trust.”57 The broken trust that continues to permeate in the African American community
is a contributing factor that leads to lower level of black participation in medical studies.58 This
mistrust and fear of medical researchers is now entrenched in the values and perceptions in the
African American community.59

51.
Id.
52.
Tuskegee Timeline.
53.
Racism and Research at 1.
54.
Tuskegee Timeline.
55.
Under the Shadow at 1773.
56.
The White House, Office of the Press Secretary, Remarks by the President in Apology for Study Done in
Tuskegee (May 16, 1997), clinton4.nara.gov/textonly/New/Remarks/Fri/19970516-898.html.
57.
Id.
58.
Under the Shadow at 1773.
59.
The Impact of Race and Genetics at 14, see also Ronald Roach, History's Burden: After Decades of
Neglect, an Academic Research Agenda is Being Built Around Health Disparities, 20 BLACK ISSUES HIGHER
EDUC. 1, 18 (May 8, 2003), available at findarticles. com/p/articles/mi_m0DXK/is_6_20/ai_101939864
[hereinafter History's Burden] which provides insight on the impact of the Tuskegee experiment with respect to
medical and public health professionals who attempt to treat diseases in the African American community; Shannon
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B. The Current Paradigm for Drug Development & Clinical Trials
Over time many legal and ethical principles have evolved to protect patients who
participate in clinical research. This section will examine international codes of ethics and
regulatory practices in the United States. The Nuremberg Code, the Declaration of Helsinki, the
Protection of Human Subjects regulation of 2009 and the NIH Revitalization Act of 1993
provide domestic and international protections to patients who participate in clinical research.
Many researchers abide by the Nuremberg Code and Declaration of Helsinki even though they
are aspirational in nature because the United States has not formally adopted these codes of
ethics. Still, the Nuremberg Code and Declaration of Helsinki were influential in the United
State’s effort to develop policies to guide research domestically.
1. International Code of Ethics
The Nuremberg Code was implemented in response to the atrocities that occurred on
concentration camps in Nazi Germany.60 The Nuremberg Code provides guidelines that should
be followed when conducting clinical research, most importantly the necessity for voluntary and
informed consent. 61 This requires that participants are legally able to consent and freely
acquiesce to participation without coercion, duress, or other unethical factors.62 In addition, the
experiment should yield fruitful results for the good of society.63 Not only should the experiment

Mortland, Local Health Officials Rally to Steam Black's Cancer Fears, CRAIN'S CLEVELAND BUS., Aug. 28,
2006, at 3 discussing African Americans mistrust of oncologist and attempts to remedy the issue by targeting
minority populations to dispel widely held views.
60.
People & Events: The Nuremberg Trials, PBS, http://www.pbs.org/wgbh/amex/nuremberg/ (last visited
March. 13 2013).
61.
Office of Human Subjects Research, Regulations and Ethical Guidelines, Nuremberg Code, Nat'l Insts.
Health, available at http://ohsr.od.nih.gov/guidelines/nuremberg.html.
62.
Id.
63.
National Institutes of Health, “Trials of War Criminals before the Nuremberg Military Tribunals under
Control Council Law No. 10,” Vol. 2, pp. 181-182. Washington, D.C.: U.S. Government Printing Office, 1949.,
available at http://history.nih.gov/research/downloads/nuremberg.pdf
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yield fruitful results, but the experiment should not involve physical or mental suffering. 64
However, the Nuremberg Code is not a part of legal jurisprudence in the United States; therefore,
researchers are not obligated to follow its mandate although it is the norm.65
Likewise, the Declaration of Helsinki is not legally binding in the United States but
provides ethical principles for researchers.66 Similar to the Nuremberg Code, the Declaration of
Helsinki is concerned with voluntary participation and informed consent.67 “It is the duty of the
physician to promote and safeguard the health of patients, including those who are involved in
medical research.”68 The Declaration of Helsinki requires that the protocol include the design
and performance of each study and any potential conflicts that may arise between physicians and
institutions financially supporting the endeavor. 69 The Nuremberg Code and Declaration of
Helsinki were influential in the United State’s efforts to deal with unethical practices in
research.70
2. U.S. Regulatory Protections
The United States passed the Protection of Human Subjects 71 to address patient
participation in research and the National Institutes of Health Revitalization Act of 1993 to

64.
Id.
65.
See Generally Ravindra B. Ghooi, The Nuremberg Code – A Critique, 2:2 Perspect. Clin. Res. 72 (2011).
66.
World Med. Ass'n, Declaration of Helsinki - Ethical Principles for Medical Research Involving Human
Subjects (2008), available at http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
67.
Id.
68.
World Medical Association, WMA Declaration of Helsinki – Ethical Principles for Medical Research
Involving
Human
Subjects,
last
accessed
(May
9,
2013)
available
at
http://www.wma.net/en/30publications/10policies/b3/.
69.
Id at para. 14.
70.
Matthew Anderson, FDA Abandons Declaration of Helsinki for International Clinical Trials, The Social
Medicine Portal, (2008) available at http://www.socialmedicine.org/2008/06/01/ethics/fda-abandons-declaration-ofhelsinki-for-international-clinical-trials/.
71.
45 C.F.R. § 46 (2009).

10

require researchers to include minorities in research. 72 This section will now examine U.S.
regulations that provide protections to participants in clinical trials.
i. The Common Rule
The Protection of Human Subjects of 2009, also known as the Common Rule, is codified
in the Code of Federal Regulations Title 45 Part 46.73 The Common Rule applies to research
involving human subjects that is financed by federal government funding; takes place at a
federally funded institution; or conducts research to support an application to the FDA.74 The
Common Rule provides detailed requirements that researchers must abide by, and include but are
not limited to, requirements for informed consent and the establishment of an Institutional
Review Board [hereinafter IRB] for oversight.75
More specifically, each institution covered by the Common Rule must have at least one
IRB, and before the covered research can begin research he or she must obtain approval from the
IRB.76 The IRB is to function as an independent body whose goal is to protect the safety and
welfare of the participants involved in the research by ensuring that the researchers are compliant
with federal regulations.77 Most important, the IRB is tasked with ensuring that possible risks to
the participants are minimized “by using procedures which are consistent with sound research
design and which do not unnecessarily expose subjects to risk.”78

72.
National Institutes of Health Revitalization Act, Pub. L. No. 103-43, § 492B(a)(1) (1993) [hereinafter
Revitalization Act].
73.
45 C.F.R. § 46 (2009).
74.
Id. at § 46.101 (2009).
75.
Id. at §§ 46.103, 46.116 (2009).
76.
Id. at § 46.109 (2009).
77.
Id. at § 46.107 (2009).
78.
Id. at § 46.111(a)(1) (2009).
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From a patient perspective, the Common Rule provides legal protection even when
informed consent is followed. 79 The Common Rule states “No informed consent . . . may
include exculpatory language through which the subject . . . is made to waive . . . any of the
subject's legal rights, or . . . to release the investigator, the sponsor, the institution or its agents
from liability for negligence.”80 The provision is particularly important because if the patient is
able to prove that the researcher fell below the acceptable standard in the performance of the
research he or she may have a cause of action. Similarly, the NIH Revitalization Act of 1993
provides protections to ensure that minorities represented in clinical research.
ii. NIH Revitalization Act of 1993
Because of the events blacks experienced with respect to clinical research, the legislature
implemented the Revitalization Act of 1993. Public Law 103-43 National Institutes of Health
Revitalization Act of 1993 [hereinafter Revitalization Act], requires that members of minority
groups be included as research participants in clinical research.81 In addition, the statute requires
the National Institutes of Health [hereinafter NIH] to develop guidelines that governs when
inclusion of minorities is inappropriate, “the manner in which clinical trials are required to be
designed and carried out,” and “the operation of outreach programs.”82 The Revitalization Act
also tasks the Director of NIH with the responsibility of ensuring that the trial is designed and
carried out in a manner sufficient to provide for valid analysis of whether the variables being
studied in the trial affect members of minority groups differently than other study participants.83
This provision is especially important as it requires cross comparison between groups and

79.
Matthew P. Gordon, A Legal Duty to Disclose Individual Research Findings to Research Subjects?, 64
Food Drug L.J. 225, 231—32 (2009).
80.
45 C.F.R. § 46.116 (2009).
81.
Id.
82.
Id. at § 492B(d)(1).
83.
Id. at § 492B(c).
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prevents researchers from isolating certain populations, unless an exception applies, without
cross referencing the drug’s effects on members of other groups.84
The Revitalization Act advances the position that minorities should be included in
research by requiring that “the Director of the Office of Research on Minority Health, conduct or
support outreach programs for the recruitment of members of minority groups as subjects in the
projects of clinical research.”85 The Revitalization Act applies broadly except in cases where
minority participation in the research “is inappropriate with respect to the health of the subjects,
is inappropriate with respect to the purpose of the research, or is inappropriate under such other
circumstances” identified by the Director of NIH.86 Similarly, minority participation in research
is exempted where there is scientific evidence establishing no significant difference between the
impacts the variables studied in the trial would have on minorities and the impact the variables
would have on participants if the inclusion was not required.87
The NIH stands firm behind the policy that minorities should be included in clinical
research “unless a clear and compelling rationale and justification establishes to the satisfaction
of the relevant Institute/Center Director that inclusion is inappropriate with respect to the health
of the subjects or the purpose of the research.”88 While the NIH policy is positive in theory and
the federal statute establishes procedural requirements such as informed consent and other
patient protections, these policies and laws are without effect if minorities do not participate in

84.
Id. at § 492B(d).
85.
Id. at § 492B(a)(2).
86.
Id. at § 492B(b).
87.
Revitalization Act at § 492B(d)(2).
88.
NIH, NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical
Research,
Amended
October
2001
available
at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
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the research.

“Black Americans tend to be under-represented in clinical trials, which are

responsible for most advances in medicine.”89
In summation, international ethical principles and domestic regulations work together to
provide patient protection. Researcher institutions that receive federal funding are incentivized
to adhere to the preapproved clinical protocol so that they can continue to receive federal funds.
In addition, IRBs are in place and provide independent oversight over the clinical process. The
Common Rule specifically protects participants because researchers cannot provide oral or
written exculpatory language to absolve themselves of liability. Even more, if a participant can
prove that the researcher was negligent, despite providing informed consent, he or she can
recover damages.
However, these legal and regulatory safeguards fall short of protecting participants
because minorities are not participating in research. While the Revitalization Act mandates that
minorities

are

underrepresented.

included

in

research,

African

Americans

remain

disproportionately

African American’s perspectives on the adequacy of legal and ethical

protections create a barrier that prevents them from participating in clinical researchers. These
perspectives are the subject of the next section.
C. Minority Perspectives on the Adequacy of Protections in Clinical Trials
According to 2011 census data, African Americans make up approximately 13.1% of the
United States population.90 As recent as 2009, African Americans comprise 15% of the 28.1%

89.
Amanda Gardner, Black Americans Still Wary of Clinical Trials Study Shows Distrust of Researchers
Lingers from Tuskegee Experiment, U.S. News & World Report, Jan. 14, 2008, available at
http://health.usnews.com/usnews/health/healthday/080114/black-americans-still-wary-of-clinical-trials.htm.
90.
US
Census
Bureau,
State
and
County
Quick
Facts
USA,
available
at
http://quickfacts.census.gov/qfd/states/00000.html.
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of minorities who participate in domestic clinical research. 91 Minority distrust of clinical
researchers is one of the reasons African Americans do not participate in research.92 “For many,
this project [Tuskegee] represents the epitome of how racism is reflected in medicine and
medical research as it is in general society.”93 Factors that weigh African American participation
in research include “distrust owing to historical research abuse and institutional racism, lack of
information and understanding of research and studies and informed consent, insufficient
recruitment efforts by researchers, social stigma, and financial considerations.”94
In the professional realm, African Americans are underrepresented in the fields of
medical and mental health, which further perpetuates levels of mistrust. 95 Corbie-Smith and
fellow researchers raise a very important point that was highlighted in their study of African
American perceptions of clinical research -- “regardless of whether the instances participants
provided as explanations are historically accurate, every instance is perceived as “real” in their
minds.”96 The past still haunts many African Americans and dealing with those deeply rooted
ideologies is an important step in increasing minority participation in research.97 “Knowledge of
research procedures and purposes is often linked to access to health care.”98 But, Corbie-Smith

91.
Department of Health and Human Services National Institutes of Health, Monitoring Adherence to the NIH
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found that African Americans have an increased likelihood of being distrustful of physicians.99
Physicians can serve as pivotal players in research protocols because they often are aware of
research and can recommend participation in the studies. However, because African Americans
are distrustful of physicians, their level of distrust will override their inclination to participate in
the study.100
Moreover, minority perspectives are shaped by the information that is available to
them. 101 Minorities do not participate in research because of lack of access to primary care
physicians who often suggest participation in clinical research and their beliefs that studies do
not apply to them, which in turn decreases minority participation in studies. 102 In addition,
because most people do not trust what they cannot understand, minorities are leery of
participating in clinical trials when they cannot understand the informed consent documents.103
African Americans, in particular, are concerned with social stigmatization and other
consequences so they shy away from medical attention.104
Conversely, not all African Americans are reluctant to participate in clinical research.
For those who choose to participate, literature suggests that altruism and volunteerism are
contributing factors.105 Another motivating factor is family encouragement.106 However, one of
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the leading barriers to minority participation in research is financial constraint; so for those who
participate in clinical protocols, financial incentive is often a deciding factor.107
Nevertheless, efforts that encourage participation are curbed when “pharmaceutical
companies discourage the recruitment of diverse populations.”108 Instead, research institutions
should focus on resolving negative perceptions. It is difficult to debunk negative perceptions and
attitudes when companies continue to contribute to those negative perceptions by discouraging
participation in research. The NIH has identified circumstances when minority participation is
excluded. 109 Therefore, efforts to discourage participation should be redirected to debunking
myths in the minority community.

III. Health Indicators and Access to Drugs
The following section will examine health indicators specifically access to drugs. Health
indicators, to be fully discussed below, identify disparities in health by using measurable factors.
Access to health is one of the measurable health indicators. Lack of access to health in turn
creates disparities in health and a trickledown effect. Lack of access creates disparities in health
care treatment which then impacts health care outcomes such as treatment for particular diseases
and life expectancies in certain populations. This section will now define access as a health
indicator and followed by an analysis that explores the impact that results because of lack of
access to health care treatment and prevention.
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A. Determinants of Health as a Policy to Support Race-Based Medicine
Access to drugs, pharmaceuticals, and research is one means to measure health. “Access
is defined as having medicines continuously available and affordable at public or private health
facilities or medicine outlets that are within one hour’s walk from the homes of the
population.”110 Research shows that the uninsured, women in particular, have a greater difficulty
accessing health care and use fewer services and preventive care.111 Approximately one in four
blacks rely on Medicaid for healthcare in comparison to one in eight whites.112 It is difficult for
minorities to access care because factors such as low reimbursement rates, administrative
burdens, and residential segregation between providers and patients create barriers to access.113
Health indicators are defined as “measurable characteristics that describe the health of a
population; determinants of health; and health care access, cost, quality and use.”114 The health
of a population can be measured in terms of life expectancy, mortality, disease incidence or
prevalence and or any other health states. 115 Health determinants are influenced by health
behaviors, health risks factors, socioeconomic and physical environments.116 Health indicators
are useful for measuring how certain identifiable groups access health care and health care
related services.117
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Researchers have examined three core areas as they relate to disparities in health.118 The
first core area researchers have explored are disparities that involve differences in the type of
treatment offered to patients.119 Socioeconomic factors have contributed to health disparities
especially as it relates to access to care.120 Not only do socioeconomic factors impact access to
care, but socioeconomic factors also affect the type of treatment offered to the patient and is a
determinate of whether the patient accepts the proposed treatment. 121 At the intersection of
health indicators and health disparities, researchers have been able to identify how race,
socioeconomic factors, and biological factors impact access to and quality of care. 122
Unfortunately, African Americans are less likely to receive medically appropriate care even
when socioeconomic and access to care factors is controlled i.e. when examining African
Americans to Caucasians in the same socioeconomic status.123
A second core area of research has focused on particular conditions and the health
outcomes that result from those various conditions.124 These studies are particularly important
for researchers in the pharmaceutical industry because it would support assertions that
researchers make when holding that certain medicines are not fit for a particular population. The
government requires that when certain racial or gender groups are excluded from research that
the researcher provide evidence that the group would be harmed in some way or that the research
would not be beneficial. Where a research can show that a particular treatment will harm a
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group s/he is insulated from governmental scrutiny. In fact, biology alone can create health
disparities and not wrongdoing on the behalf of researchers.125
The third core area of research explores disparities in health status for example
differences in life expectancy and prevalence of certain diseases for certain groups.126 Health
status directly correlates with gender.127 Men have a life expectancy that is five years less than
that of women.128 The Centers for Disease Control uses life expectancy to measure health.129
From 1980 to 2008, life expectancy at birth increased six years for males rising from 70 to 76
and four years for females from 77 to 81 years.130 However, African Americans still lag behind
in life expectancy when compared to their Caucasian counterparts.131 African Americans have a
life expectancy of 70 years for males compared to 78 years for Caucasian males and 77 years for
African American females compared to 83 years for Caucasians females.132 “That disparities in
health status mirror patterns of historical discrimination in society is at least cause for alarm, and
perhaps action as well.”133 There are many factors that impact health disparities and access to
health care and it is crucial that the actual cause is identified to remedy and address the problems
African Americans face as identified by health indicators. One way to identify and address
health problems in the African American community is through race-based medicine.
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B. Race-Based Medicine a Misunderstood Clinical Research Practice
Race-based medicine is a subset of pharmacogenomics, which involves the sequencing of
the human genome to better understand disease and pharmaceutical mechanisms for an
individual patient.134 Race-based medicine can be defined as “screening, diagnosis, or treatment
based on the appointment of an individual to a specific subpopulation associated with his
physical characteristics, language, or, perhaps, surname, which is presumed to serve as a marker
of the geographic origins of one’s ancestors.”135 One goal of race-based medicine is to explore
racial ancestry to better identify genetic predispositions for diseases.136 It is crucial that patients
and researchers understand the difference between social race and biological race.137 Social race
as distinguished from biological race is the ideology that taking an individual’s perception and
combining society’s perception of the individual impact the ethnic or racial group within which
the individual is a member.138 On the other hand, biological race examines race in the context of
ancestry.139 Although there is a history of racially motivated research, some argue that race is no
longer a factor that impacts research.140
Race-based medicine is highly debated both in theory and in practice because on the one
hand race-based medicine could advance medicine, but on the other hand it could negatively
perpetuate stereotypes and ideologies of certain groups. “Although it is recognized that ideology
influences the social meaning of race, it is usually assumed that there is a separate, prior
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scientific understanding of race that is not contaminated by politics.”141 Critics of race-based
medicine argue that race should not be used because “race has no coherent meaning, and
therefore, reliance upon it for research or treatment purposes can be confusing at best and can
lead to significant adverse consequences at worst.”142 However, the truth remains that there are
differences in life expectancy between racial groups, differences in metabolic rates of nicotine
from cigarette smoking, and differences in hypertension rates.143 Examining how race and other
health indicators factor into overall health is important so that healthcare players such as
lawmakers, researchers, doctors, and community activist; can better close the divide between
racial groups and health care disparities.
Scholar of race, gender and law, Dorothy Roberts, identifies “conservative colorblind
ideologists” as those who assert that differences between racial groups are based on unbiased
market operations, that racism is no longer a factor socially, and that social policies should not
use race as a basis for policy determinations.144 Conservative colorblind ideology is an extreme
view for some to conceptualize. However, there is some merit to the idea in the biological
research realm. In biological research, race remains a factor in medical research and because of
these differences between groups it is important for researchers to fully explore these differences
when developing medicines.145
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Acknowledging the fact that there are differences between races is key in closing the gap
in health disparities. The next step is to make clear that while there are biological differences
between groups, the race of the individual will not interfere with the ethical obligations of the
researcher. The conservative’s view of racial colorblindness intersects with the identity-based
ideologist because both groups share the view that race matters in medicine. Identity-based
ideologists are race conscious and assert that programs that use race as a basis for funding are
important for advancing medicine.146 Race-conscious efforts are implemented to correct past
wrongs and in doing so also advance current colorblind paradigms.147 One example that has
been particularly beneficial for African Americans is the drug BiDil. BiDil is a drug specifically
targeted at African Americans and has created an alliance between the pharmaceutical world and
racial organizations such as the National Association for the Advancement of Colored People
(NAACP). As a result, the pharmaceutical company and national association can work together
to close the gap in health disparities.148

IV. BiDil
The drug BiDil has an interesting past despite its positive results in the African American
community. The first study of BiDil failed to receive Federal Drug Administration [hereinafter
FDA] approval.149 The first FDA application was submitted in 1997, but the results failed to
show sufficient statistical efficacy for a multiracial population with heart disease.150 “On the
recommendation of members of FDA's advisory committee, NitroMed re-examined the clinical
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trial data along racial lines.”151 It was from this data that the researchers began a second study
that later would receive FDA approval. The drug is criticized for promoting counterproductive
healthcare policy. The FDA, by approving BiDil, also approved a biological model for race.152
“Because the FDA had no clinical evidence on which to base its drug approval for a specific
race, the approval is implicitly based on an assumed biological difference between black and
nonblack patients.”153 The clinical researchers failed to cross compare populations to determine
whether there was a significant difference when determining the efficacy of the drug.154 This
section will now examine how the drug BiDil was developed and its social, political, and
commercial implications.
1. Development of the Drug BiDil
The FDA announced in June 2005 that it approved for the first time a pharmaceutical
drug specifically targeted for African Americans.155 BiDil is a combination of two generic drugs
hydralazine and isosorbide dinitrate.156 BiDil works to treat heart failure by relaxing the blood
vessels surrounding the heart.157 The drugs themselves are not new to the market, but rather their
combination and concentration is a new drug. It is widely viewed by the public as the world’s
first “ethnic” drug.158
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The study was entitled the African American Heart Failure Trial [hereinafter A-HeFT].159
The study enrolled 1,050 black patients who had New York Heart Association class III or IV
heart failure with dilated ventricles.160 A-HeFT was a randomized, placebo-controlled, doubleblind trial with patients recruited at 161 centers in the United States. 161

Half of the study

participants were treated with the combination drug and the other half the placebo along with
standard therapy used for heart failure.162 This study in comparison to the unethical studies in
the early 20th century were reviewed and approved by the institutional review board at each site
and all patients gave written informed consent. 163 The study sponsor was NitroMed, a
Massachusetts based biotechnology firm.164
This study is important for two reasons. First, the study was proven efficacious for a
group that traditionally lacks access to proper medical care. Second, the study is important
because it provides empirical evidence that researchers are able to implement ethical studies that
do not compromise the lives of the study participants. In the A-HeFT study, independent
committees assessed all primary and secondary end points, reviewed data on safety, and oversaw
the two prespecified interim analyses, which were performed solely to assess the adequacy of the
sample size.165
Although the study was terminated prematurely because many of the patients on the
placebo experienced higher mortality, the results showed that patients who were treated with the
drug combination hydralazine and isosorbide dinitrate along with standard therapy for heart
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failure had an increased chance of survival among black patients with advanced heart failure.166
While all of the study participants were African American, the trial investigators presented that
drug as effective in other racial groups as well.167
The A-HeFT study published by the New England Journal of Medicine establishes that
the drug is efficacious in the population studied, African Americans. 168 There was a 43%
reduction in mortality rate in the group given the combination drug, supporting the conclusion
that the drug controls heart failure.169 The drug BiDil is wiedly criticized on social and political
levels in spite of the drugs proven efficacy in the African American population.
2. Criticisms of BiDil
Critics of the A-HeFT study do not believe that the drug can be marketed as beneficial for
African Americans because there was no comparison population.170 “The only responsible claim
that can be made on the basis of these trials is that BiDil works in some people who have heart
failure.”171 The study has been criticized on three levels: scientific, commercial and political.172
“By claiming that race, a political grouping, is important to the marketing of drugs and that racebased drugs can reduce health disparities, which are caused primarily by social inequality, those
who promote racialized medicine have made it a political issue.”173
Scientifically there are widespread criticisms to the use of race-based medicine; the more
important question to explore is whether race-based medicine can reduce health disparities.
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Medical research should by no means perpetuate stereotypes and racism, but if race-based
medicine can close the gap in the health indicators that relates to access to care, perhaps racebased medicine is a solution and not an actual problem. Next, this paper will address whether
the critiques of BiDil address closing the gap in health disparities or are aimed at some other
social issue. It is important, as highlighted earlier, to maintain a dividing line between race as a
sociological issue and race as a biological/medical issue.
In the political arena, the FDA is criticized for approving the drug BiDil because the drug
is targeted for a specific population, African Americans. 174

Historically, the FDA has

discouraged clinical research practices that take advantage of marginalized groups. 175 It is
argued that the FDA’s decision “may be a setback to scientific discourse on therapeutics and
may be specifically deleterious to efforts aimed at addressing disparities in health and health
care.”176 BiDil has further been criticized for exploiting the African American community for
corporate profit and two a poor precedent of racial segregation in medicine.177 Even more, the
drug was marketed as a race specific treatment, but in reality there was evidence that the drug
was effective across racial lines.178
Commercially, the drug is criticized for its price because the generic drug was priced
significantly lower at approximately $1.50-$3.00 while BiDil was priced at $5.40-$10.80 per day
for treatment. 179 It would seem that if the goal were to increase access to health care and
decrease disparities in the provision of health, the drug manufacturer would have priced the drug
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in a range that was affordable for the population. 180 Despite the discounts and gratuitous
availability of the drug for certain groups, cardiologists argued that the drug cost exceeded many
patients’ financial ability to pay.181 However, accounting for insurance and other factors it is
arguable whether the cost of the drug is commercially exploiting the African American
population.
Researchers have attempted to remedy a healthcare disparity by disseminating
information that may not be based on scientific evidence. 182 The question then becomes are
researchers advancing genetic revolution or are they perpetuating stereotypes?183 The FDA is
sending mixed signals by approval of the drug BiDil. On the one hand, researchers are required
to follow certain clinical guidelines when race is a factor.184 On the other hand, the FDA has
approved the use of race as a factor when it seems to decrease health disparities, but it is argued
that this erodes the advancements that were made to create equal treatment in the clinical
research setting.185

V.

Race-Based Medicine as a Means to Reduce Health Disparities
Despite the controversy surrounding the drug BiDil, there are benefits to the drug’s use.

There are many theories that describe why African Americans are more likely to die of heart
failure in comparison to whites. 186 Some contributing factors to higher prevalence of heart
failure in African Americans in comparison to whites include delay in diagnosis treatment,
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physical inactivity, and smoking. 187 A group of social scientists reviewing genomic science
argue that “we must continue to do research on race in medicine because whatever its biological
basis race remains a very important social construct, and as such, it has tremendous power to
influence health and illness.”188 There are social and cultural factors that can contribute to higher
prevalence of certain diseases in certain populations and exploring drugs such as BiDil allows
researchers to examine these crucial contributing factors. 189 “Simply eliminating race as a
variable in medical research would undermine our ability to detect these factors and can
therefore hardly be helpful in reducing the serious disparities that remain a problem in American
medicine.”190
The development of the drug BiDil is a reason to celebrate not only for the scientific
advancement, but also for the cultural and social advancement. 191 In light of the historical
injustices surrounding African Americans and scientific research, the development of BiDil
should be seen as a step in the direction of removing discrimination in research.192 When race is
a contributing factor in research it is not to perpetuate racism or discrimination, but rather race is
a “placeholder” so that researchers can fully examine differences among groups of people.193
“Finding these variations (and their physiological manifestations) and then linking these
variations to differences in therapeutic efficacy” is the benefit race-based medicine.194
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Race-based medicine as a research approach is most supported by the development of
the drug BiDil.195 Creating BiDil is one of the first attempts to remedy claims of misrecognition
in research and also increase minority participation in clinical trials.196 African Americans have
distrusted researchers since the occurrence of the racially charged atrocious acts, slavery and the
Tuskegee experiment.197
BiDil should be viewed as not only a drug development, but also as a socially progressive
movement that can increase minority participation in research and also prove that researchers
respect African Americans and have their best interest in mind. In the following section, I will
explore recommendations for dealing with lack of minority participation in clinical trials by way
of public health and community based approaches that educate and encourage minorities to trust
their physicians and researchers.

VI.

Recommendations and Conclusion
Remedying past discrimination in clinical research to encourage minorities seems like a

formidable task. “The family medicine community ought to encourage continued action to
reduce health disparities, to promote research that addresses the psychological and social
contributors to ill health alongside the biological factors.”198 Unfortunately, minorities remain
very distrustful of physicians and clinical researchers. Racial tensions have loomed among
African Americans for decades, but if race-based medicine can remedy health disparities it
should be pursued. One perspective to address this challenge is a public health perspective. The
World Health Organization (WHO) defines public health as “all organized measures (whether
public or private) to prevent disease, promote health, and prolong life among the population as a
195.
196.
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198.
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whole. Its activities aim to provide conditions in which people can be healthy and focus on entire
populations, not on individual patients or diseases.”199 Disparities in health care access trickle
down and have various effects on African Americans. Public health would support measures
that prevent disease and prolong life among populations, in this case African Americans. Public
health initiatives that promote increased transparency in clinical trials would help to develop
bonds of trust between minorities and researchers.
In 2010, the University of Minnesota received a $3.8 million dollar grant from the
National Institutes of Health’s National Cancer Center on Minority Health and Health
Disparities.200 Researchers are aware that, while there are racial differences in prevalence among
diseases, social and environmental factors also impact health disparities.201 “We need not shy
away from the potential benefits of race-conscious therapeutics, but we should manage its
downside risks, greater awareness among physicians and the public that race is at best a
placeholder for other predispositions, and not a biologic verity, would be a first step.” 202
Medical researchers and clinical researchers alike should not avoid racial differences in groups
because it does these groups a disservice.

Instead, researchers should face these racial

differences head on to further understand why certain diseases are more prevalent among
minorities. The efforts at the University of Minnesota are one step in that direction. The
University of Minnesota has identified a group of people, African Americans, who suffers with a
health issue and aims to help remedy that issue by educating minorities and encouraging
participation in clinical trials.
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In addition to university sponsored events, primary care physicians assist in building trust
among minorities. Physicians interact with patients on a one-on-one level and are better able to
address distrustful concerns. To address patient distrust, physicians should increase dialogue and
find out what concerns minorities face. Preconceived notions and ideas about researchers may
be deeply engrained in African American culture, but physicians should take the angle that
quality of life increases with better health and with better health researchers must understand
how to remedy health issues and without minority participation in research there is no way to
understand why illnesses plague that group.
Moreover, legislative initiatives that subsidize costs to increase minority participation in
research would encourage pharmaceutical companies to expend more money on minority
recruitment. In pediatrics for example the government awards financial incentives for research.
The Best Pharmaceuticals for Children Act passed in 2002 provides pharmaceutical companies
with extended market exclusivity on drugs developed for children.203 Because manufacturers
have longer market exclusivity on drugs they are able to increase profit which is also an
incentive for pharmaceutical companies to research illnesses facing children. Similarly, the
government should offer some incentive, be it longer market exclusivity or the government
subsidizing costs to address distrust among minorities to in turn increase participation.
All in all, it is challenging remedying distrust in African Americans because of past
events and distrustful attitudes carrying from generation to generation. On a simpler level,
having participants in research attest to their experiences in clinical trials could help debunk
negative ideologies.

The fact remains that there are health care disparities; however, taking a

public health approach, encouraging relationships between primary care physicians and patients
and increasing financial incentives could begin to remedy distrustful attitudes. Addressing the
203.
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issue head-on will then allow greater freedom in clinical research so that researchers can
examine race-based issues without public outcry and distrust.
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